ATAD Corp. is a Seoul-based technology company building an AI-driven multi-cloud operating platform that helps teams run AWS, Azure, and GCP environments from one place. Its flagship product, ODiiN, uses AI to forecast and self-heal infrastructure problems, claiming up to 80% cost savings and large productivity gains. Founded in 2023 by cloud and cybersecurity specialists, ATAD pairs cloud automation with a security stack built on AI, multi-factor authentication, and zero-knowledge proofs, and also runs Heiimdahl (a multi-LLM monitoring gateway) and Kraton (a blockchain-based decentralized VPN). The company has raised about $3.36M and holds a growing portfolio of patents in multi-cloud integration and secure data distribution.
Avelos Therapeutics is a Seoul-based clinical-stage oncology biotech founded in 2021 that designs small-molecule drugs for 'undruggable' cancer targets using synthetic lethality, DNA damage response (DDR), and cell-cycle biology. Its lead program, AD1208, is a first-in-class oral MASTL kinase inhibitor now in a Phase 1/2a solid-tumor trial. Backed by KRW 30 billion (~$21.7M) across seed, Series A, and a 2024 Series B, the roughly nine-person team is building a biomarker-driven pipeline of four anti-cancer candidates aimed at a future KOSDAQ listing.